We are live on ! Find out more
ORKA icon

Oruka Therapeutics

26 hedge funds and large institutions have $5.02M invested in Oruka Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

24% more funds holding

Funds holding: 21 → 26 (+5)

0.34% less ownership

Funds ownership: 17.85% → 17.51% (-0.34%)

27% less capital inflows, than outflows

Capital inflows: $298K | Capital outflows: $408K

31% less call options, than puts

Call options by funds: $148K | Put options by funds: $213K

Holders
26
Holders Change
+5
Holders Change %
+23.81%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
8
Reduced
3
Closed
1
Calls
$148K
Puts
$213K
Net Calls
-$65K
Net Calls Change
-$99K

ORKA Hedge Fund Activity: Q1 2023 in Review

26 of the 6,290 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2023, worth a combined $5.02M — down 18% from $6.09M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ORKA positions and 1 closed out — a net gain of 5 holders — while 8 added to existing stakes and 3 trimmed.

The largest buyer was Group One Trading, opening a new position worth an estimated $50.5K. The largest seller was BML Capital Management, cutting an estimated $332K.

  • 26 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2023, up from 21 in Q4 2022.
  • Funds reported $5.02M of Oruka Therapeutics stock for Q1 2023, down 18% quarter-over-quarter.
  • 6 funds opened new Oruka Therapeutics positions in Q1 2023 and 1 closed out, a net change of +5 holders.
  • The largest Oruka Therapeutics buyer in Q1 2023 was Group One Trading, an estimated $50.5K added.
  • The largest Oruka Therapeutics seller in Q1 2023 was BML Capital Management, an estimated $332K sold.

Based on aggregated 13F filings for Q1 2023.